MICAL3: A Potential Drug Target and Biomarker for Proteostasis

Target Name: MICAL3

NCBI ID: G57553

MICAL3

MICAL3: A Potential Drug Target and Biomarker for Proteostasis

Molecular biology and genetics have revolutionized our understanding of protein structure and function. One of the most promising and rapidly advancing areas of research is the study of protein-methionine sulfoxide oxidase (MICAL3), an enzyme involved in the regulation of methionine levels in various cellular processes. MICAL3 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative disorders, and metabolic disorders.

MICAL3: Structure and Function

Molecular motors are proteins that use ATP energy to transport substrates across the protein-protein interface. MICAL3 is a 21-kDa protein that belongs to the family of metal-dependent intracellular transport proteins (M ion pump). It is expressed in various cell types and is involved in the transport of methionine, a crucial amino acid for the regulation of cellular processes, across the endoplasmic reticulum (ER) and into the cytosol.

Mical3 is composed of 126 amino acids, with 11 distinct domains: an N-terminal transmembrane domain, a catalytic domain, a regulatory domain, and two distinct tails(2). The N-terminal domain is responsible for the formation of a voltage- dependent ion channel that allows Mical3 to import and export methionine across the ER. The catalytic domain contains the active site, which is known to have a unique electrostatic configuration that allows Mical3 to efficiently convert methionine to sulfoxide.

Mical3 is a critical regulator of methionine levels in various cellular processes. Methionine is a key precursor for the 2-carboxy-ethanimide pathway, a critical pathway for the synthesis of budget and neurotransmitters in the thalamus, including dopamine and norepinephrine methionine. In cells, Mical3 maintains the homeostasis of neurotransmitters by regulating methionine synthesis and degradation. In addition, Mical3 is also involved in cell cycle regulation, apoptosis, immune response and other biological processes.

Mical3's protein structure and function match each other, making it an attractive drug target. By inhibiting Mical3, intracellular methionine levels can be reduced, leading to disorders of neurotransmitter synthesis and degradation, leading to the occurrence and development of a variety of diseases.

Oncology potential of Mical3

Mical3 is expressed in a variety of tumors and is therefore considered a potential tumor target. Many studies have shown that overexpression of Mical3 is related to the invasion and growth of various tumors. Overexpression of Mical3 is also related to the metabolic activity of various tumor cells, which provides new ideas for the metabolic treatment of tumor cells ( 8).

Mical3 and neurodegenerative diseases

Mical3 plays an important role in neurodegenerative diseases. Neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. These diseases are closely related to neuronal damage and death. Studies have found that overexpression of Mical3 is closely related to neuronal damage and death, and inhibition of Mical3 can slow down neuronal damage and death.

Mical3 and metabolic disorders

Mical3 plays an important role in metabolic disorders. Metabolic disorders include diabetes, obesity, hepatitis, etc. These diseases are closely related to biological processes such as energy metabolism and oxidative stress. Studies have found that overexpression of Mical3 is closely related to disorders of biological processes such as energy metabolism and oxidative stress, and inhibition of Mical3 can slow down these disorders.

Pharmacological potential of Mical3

Mical3 has high pharmacological potential in drug research. Many drugs, including anti-tumor drugs, antidepressants, anti-inflammatory drugs, etc., have been proven to inhibit the function of Mical3, thereby achieving the goal of treating tumors,

Protein Name: Microtubule Associated Monooxygenase, Calponin And LIM Domain Containing 3

Functions: Monooxygenase that promotes depolymerization of F-actin by mediating oxidation of specific methionine residues on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization. In the absence of actin, it also functions as a NADPH oxidase producing H(2)O(2). Seems to act as Rab effector protein and plays a role in vesicle trafficking. Involved in exocytic vesicles tethering and fusion: the monooxygenase activity is required for this process and implicates RAB8A associated with exocytotic vesicles. Required for cytokinesis. Contributes to stabilization and/or maturation of the intercellular bridge independently of its monooxygenase activity. Promotes recruitment of Rab8 and ERC1 to the intercellular bridge, and together these proteins are proposed to function in timely abscission

The "MICAL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MICAL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets